AI summary by TwinMind
The Curious Case of the Disappearing Polymorph
Asianometry
17m 18s
FDA Approval and Initial Production (1996-1998)
- Early 1996: FDA approved revolutionary HIV drug ritonavir (Norvir)
- Abbott Labs began immediate production for tens of thousands of HIV patients
- 240 lots of drug tablets produced without incident
- Early 1998: New drug form spontaneously appeared, rapidly spread through entire factory
- Production halted completely
Drug Polymorphism Background
- Active pharmaceutical ingredients exist in multiple solid forms
- Amorphous: molecules jumbled without defined shape
- Crystalline: molecules arranged in orderly lattice
- Polymorphism discovered 1821 by German chemist Eilhard Mitscherlich
- Same chemical composition, different physical properties
- Examples: aragonite vs calcite (both calcium carbonate), glycine amino acid
- Polymorphs affect: texture, shelf life, room temperature stability, light/air exposure
- Polymorphs can transform under right conditions
- Aspirin example: Form 2 discovered 2004 via computer simulation, confirmed 2005
HIV Treatment Evolution
- HIV leads to AIDS if untreated
- First drugs: nucleoside analog reverse transcriptase inhibitors (NRTIs)
- AZT most famous
- Virus eventually develops resistance
- 1995: New class emerged - protease inhibitors
- Different mechanism: blocks HIV protease enzyme
- Prevents viral reproduction by stopping protein chain chopping
- Significant breakthrough in HIV treatment
Ritonavir Development
- 1982: Abbott noticed HIV protease resembled renin enzyme (blood pressure research)
- Scientists re-engineered renin work to block HIV protease
- Computer-assisted design generated hundreds of candidates
- 1992: Three candidates chosen, two failed
- ABT-538 (ritonavir) showed instant results
- December 1995: Human study showed significant viral load reduction
- White blood cell counts nearly doubled
- Side effects: diarrhea, nausea, headaches
- March 1996: FDA advisory panel recommended approval
- January 1996: Abbott began production before approval
- Demand incredible: Canadians traveled to US, 224 bottles stolen from Canadian offices
- Combined with other drugs for highly active anti-retroviral therapy (HAART)
The Crisis Emerges (Early 1998)
- 2 years into market entry: Chicago factory noticed problems
- Ritonavir sold in two formulations: liquid and semi-solid capsule
- Capsule form: drug dissolved in semi-solid wax substance
- Early 1998: Capsules started failing dissolution tests
- Drug precipitating out of capsules, separating into solid crystals
- Microscope examination: Expected rod/rectangular crystals, found fine needle clusters
- X-ray powder diffraction confirmed new polymorph: Form 2
Form 2 Characteristics
- More thermodynamically stable than Form 1
- All hydrogen bonds satisfied
- 5 times less soluble in ethanol-water solutions
- Form 1 manufacturing process incompatible with Form 2
- Extremely contagious: 1 part per million can convert entire batch
- Form 2 took over Chicago factory's entire output
- Scientists traveled Chicago to Italy factory to investigate
- Italian factory's ritonavir converted to Form 2 after visit
Supply Crisis and Patient Impact
- July 1998: Drugstores running through existing capsule supplies
- Abbott held regular press conferences
- Quote: "No gradual trend, something occurred that caused new form... no early warning, didn't know how to detect, test for, prevent, or clean it"
- 70,000 patients relying on drug for cocktails
- Abbott provided liquid formulation as substitute
- Liquid version worked but tasted extremely bad ("vile")
- Patient quote: "Like awful liquor that makes mouth and gut tingle and sting"
- Suggested mixers: chocolate milk, Ensure, granola bars, toast with peanut butter, Nutella
- Additional concerns: 43% alcohol content, storage requirements in warmer temperatures
Abbott's Response Efforts
- Hundreds of scientists assigned dual approach:
- Solid formulation for Form 2 variant
- New pathway to consistently produce Form 1
- Extensive efforts to restore Form 1 production:
- Countless experiments
- Reconditioned facilities
- Rebuilt facilities and new lines
- Visited organizations worldwide for clean environments
- Every location contaminated with Form 2 within 5-6 weeks
- Dr. Eugene Sun declared: "Never be able to go back to Form 1"
- Form 1 capsules would be "gone supposedly for good"
Resolution and New Formulation
- Prior to crisis: Abbott developing soft gelatin capsule
- March 1999: Began FDA approval process for gel capsule with Form 2
- July 1999: FDA approved new gelatin capsule format
- Crisis officially ended
- Financial impact: $250 million potential revenue lost
- Cost: hundreds of employees worked 24/7, gave up summers/vacations
Later Discoveries
- Scientists later found ways to convert Form 2 back to Form 1 (time-consuming, careful effort)
- 2010: Hot melt extrusion method discovered for Form 1 capsules
- Total of 5 forms discovered:
- Form 3: emerges when exposed to liquid solvent
- Form 5: Form 3 exposed to water
- Form 5 can convert to Form 1
Origin Theory
- Form 2 source unclear
- Abbott's conclusion: manufactured Form 1 lot had liquid solvent dry up in manufacturing cycle
- Created residue that crystallized into Form 2, contaminating equipment
- Later paper suggested mechanical milling action (with/without liquid) can cause Form 1 to transition to Form 2 seeds
- Molecule size and complexity likely why Form 2 not discovered initially
Industry Impact
- 2008: Similar crisis with Parkinson's drug rotigotine (Neupro patch)
- New crystal polymorph crystallized on patches, reducing effectiveness
- Product withdrawn and reworked
- Ongoing concern for pharmaceutical manufacturing ramp-up
- Comparison to Kurt Vonnegut's "Cat's Cradle" Ice-nine concept
